Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T16:15:49.532Z.
Calculation as of: 2026-10-06T16:15:49.532Z.
Quote observation: 2026-10-06T16:15:16.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6a2f90c369cc2bba861e7882df5fb589e6a534c6c6a3ec3aca589af2a274c9b5
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Anteris Technologies Global Corp.
Market Cap
$690.28M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$672.27M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$717.52M
EBITDA Yield
N/A
TTM Avg
4.15%
3Y Avg
4.09%
5Y Avg
4.09%
Market Cap
$718.54M
EBITDA Yield
34.93%
TTM Avg
23.06%
3Y Avg
19.27%
5Y Avg
16.31%
Market Cap
$720.01M
EBITDA Yield
N/A
TTM Avg
0.40%
3Y Avg
0.67%
5Y Avg
0.67%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Anteris Technologies Global Corp. (AVR) | $690.28M | N/A | N/A | N/A | N/A |
| Annexon, Inc. (ANNX)vs › | $681.58M | N/A | N/A | N/A | N/A |
| Helus Pharma Inc. (HELP)vs › | $681.21M | N/A | N/A | N/A | N/A |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $672.27M | N/A | N/A | N/A | N/A |
| MiMedx Group, Inc. (MDXG)vs › | $670.50M | 3.81% | 10.03% | 6.88% | 6.20% |
| Olema Pharmaceuticals, Inc. (OLMA)vs › | $714.33M | N/A | N/A | N/A | N/A |
| Avalo Therapeutics, Inc. (AVTX)vs › | $717.52M | N/A | 4.15% | 4.09% | 4.09% |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $718.54M | 34.93% | 23.06% | 19.27% | 16.31% |
| Cytek Biosciences, Inc. (CTKB)vs › | $720.01M | N/A | 0.40% | 0.67% | 0.67% |
| ArriVent BioPharma, Inc. (AVBP)vs › | $659.73M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
